---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-056480"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-04-22T23:59:59+00:00"
generated_at: "2026-05-23T09:27:22.312648+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tivic Health briefed White House and FDA on TLR5 candidates and ncVNS; positive interest noted

## Summary
- On April 17, 2025, briefed White House senior leadership on Entolimod for acute radiation syndrome and need for advanced treatments.
- Met with FDA to discuss expedited pathways for Entolimod, Entolasta (second-gen TLR5 agonist), and non-invasive cervical VNS technology.
- Previous U.S. government funding from BARDA, NASA, DTRA, DoD, and Army for TLR5 program highlighted.
- Positive interest in military/defense applications; FDA explored breakthrough device designations for ncVNS after clinical work.
- CEO Jennifer Ernst expects continued discussions as programs progress toward potential FDA approval.

## SEC filing metadata
- accession: 0000950170-25-056480
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-04-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025056480/0000950170-25-056480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025056480/tivc-20250422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-056480
- JSON: https://secwatch.observer/filing/0000950170-25-056480.json
- Plain text: https://secwatch.observer/filing/0000950170-25-056480.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.